- Home
- HRTX vs AGD Comparison
HRTX vs AGD Comparison
Compare HRTX & AGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRTX | AGD |
|---|---|---|
| Founded | 1983 | 2006 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.9M | 309.7M |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | HRTX | AGD |
|---|---|---|
| Price | $1.28 | $12.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 61.2K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.13% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $155,097,000.00 | N/A |
| Revenue This Year | $8.98 | N/A |
| Revenue Next Year | $11.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.60 | N/A |
| 52 Week Low | $1.00 | $8.20 |
| 52 Week High | $2.68 | $9.78 |
Technical Indicators
Market Signals| Indicator | HRTX | AGD |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 50.41 |
| Support Level | $1.19 | $12.16 |
| Resistance Level | $1.42 | $12.60 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 30.65 | 17.14 |
Price Performance
Historical ComparisonAbout HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About AGD abrdn Global Dynamic Dividend Fund of Beneficial Interest
Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors, among others.